$DMAC News

DiaMedica (DMAC) Q2 2026 Earnings Call Transcript

All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy

DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ...

DiaMedica Therapeutics Inc. Q2 2026 Earnings Call Summary

DiaMedica Therapeutics Q2 Earnings Call Highlights

DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript

HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Target

DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

DiaMedica Therapeutics Q2 EPS $(0.19) Beats $(0.20) Estimate

DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026

DiaMedica Therapeutics (DMAC): BioTech with Breakthrough Potential

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction

DiaMedica Therapeutics Doses First Patients In Its Phase 2 Trial Of DM199 For The Treatment Of Fetal Growth Restriction

DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program

DiaMedica Receives FDA Written Response About The Need For Additional Nonclinical Reproductive Toxicity Data To Support Continued Development Of DM199 For The Treatment Of Preeclampsia

DiaMedica (DMAC) Q4 2025 Earnings Transcript

DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026

DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial

DiaMedica Therapeutics Announces 75% Enrollment In Its Phase 2/3 ReMEDy2 trial of DM199 In Patients With Acute Ischemic Stroke